PubMed Daily Triage — 2026-07-10

Run date: 2026-07-10 | Attempt: 1 of 3 | Window: CRDT 2026-07-09 → 2026-07-10
Model: anthropic/claude-sonnet-4-6 | Total articles: 20 (15 HIGH · 5 MEDIUM · 0 LOW)

🔴 SENTINEL FINDINGS (out-of-watchlist HIGH priority)

PMID 42425122 — Lancet | Score 9/10

Temocillin versus carbapenems for 3GCR-E bacteraemia (ASTARTÉ): multicentre Phase 3 RCT
Dezza FC, Pulido LB, … Rodríguez-Baño J · Lancet · 2026-07-09
DOI: 10.1016/S0140-6736(26)00760-9

Key finding: Temocillin non-inferior to carbapenems for bacteraemia caused by third-generation cephalosporin-resistant Enterobacterales (74% vs 73% clinical success, difference 0.3%, 95% CI −7.7% to ∞; non-inferiority p=0.017) across 328 patients in 29 Spanish hospitals.

A Phase 3 RCT in The Lancet validating temocillin—a narrow-spectrum β-lactam long neglected outside Belgium—as a carbapenem-sparing option for AMR bacteraemia. Directly addresses a global antibiotic stewardship priority. Investigator-initiated with no industry sponsor influence on primary endpoint. Immediate clinical impact for AMR management.

PMID 42424436 — Science | Score 8/10

Autonomous biomedical research with an artificial intelligence agent (Biomni)
Huang K, Zhang S, Wang H, … Snyder MP, Cong L, Regev A, Leskovec J · Science · 2026-07-09
DOI: 10.1126/science.adz4351

Key finding: Biomni (Stanford/Arc Institute/Genentech) autonomously executes biomedical tasks across 25 domains—causal gene prioritisation, drug repurposing, rare-disease diagnosis, microbiome analysis, molecular cloning—without task-specific tuning, via LLM reasoning + retrieval-augmented planning + code execution.

Landmark Science paper from Snyder, Regev, and Leskovec labs. First general-purpose AI agent benchmarked at scale across the full biomedical research action space. Direct relevance to rare-disease diagnosis and drug discovery pipelines. Not a clinical tool yet, but fundamentally accelerates all watchlist domains.

🟥 TOPIC 1: Hematologic Malignancies (AML, MDS, CLL, MPN, Lymphoma)

78 found · 15 reviewed · 3 HIGH · 1 MEDIUM

PMID 42425121 — Lancet | Score 10/10 ★ TOP ARTICLE

BRUIN CLL-322: pirtobrutinib + venetoclax-rituximab vs VR in R/R CLL (Phase 3 RCT)
Davids MS, Eyre TA, Woyach JA, … Ghia P, Wierda WG · Lancet · 2026-07-09
DOI: 10.1016/S0140-6736(26)01204-3 | Open access (CC BY 4.0)

Key finding: Adding pirtobrutinib (non-covalent BTKi) to venetoclax-rituximab improved PFS in 639 R/R CLL patients (HR 0.547, p=0.0001); 24-month PFS 87% vs 72%; benefit consistent across prior covalent BTKi subgroup (80% of cohort); supports PVR as new fixed-duration standard of care.

The first Phase 3 RCT of a non-covalent BTKi in a fixed-duration regimen for CLL. Addresses the critical post-covalent-BTKi relapsed setting with the largest progression-free survival improvement seen in a CLL Phase 3 trial in years. Immediate practice-changing potential. Eli Lilly-sponsored; masked IRC review strengthens validity.

PMID 42426209 — NPJ Digit Med | Score 9/10

AI algorithm enhances early detection of PNH in real-world settings (1.3M patients)
Dewor R, Dabrowski MJ, … Dubiela P, Lis K, Basak G · NPJ Digit Med · 2026-07-09
DOI: 10.1038/s41746-026-02980-0 | Open access

Key finding: AI algorithm deployed across 14 Polish healthcare organizations screened 1,307,140 patients; 356 high-risk individuals identified; 13/119 confirmed PNH (PPV 10.9% vs 6.9% conventional); retrospective analysis revealed preventable diagnostic delays of 74–1,337 days.

Real-world prospective AI deployment for ultra-rare hematologic disease at population scale. Demonstrates EHR-based AI screening is actionable in routine care and identifies atypical PNH presentations that conventional screening misses. AstraZeneca-sponsored but prospective deployment validates real-world utility.

PMID 42425157 — J Natl Compr Canc Netw | Score 7/10

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026
Gerds AT, Gotlib J, Abdelmessieh P, … Bergman MA, Hochstetler C · JNCCN · 2026-07-01
DOI: 10.6004/jnccn.2026.0034

Key finding: Updated NCCN MPN guidelines focusing on myelofibrosis management, including JAK inhibitor sequencing and emerging therapies for high-risk MF; standard-of-care reference for MF, PV, and ET.

PMID 42425977 — Nat Commun | Score 6/10 [MEDIUM]

Iron homeostasis–epigenetic axis drives -7/del(7q) AML (ABCB8 tumour suppressor)
Zheng J, Peng Y, Deng X, … Chen C, Liu Y · Nat Commun · 2026-07-10
DOI: 10.1038/s41467-026-75292-2 | Open access

Key finding: CRISPR screen identifies ABCB8 (mitochondrial iron transporter, 7q) as novel tumour suppressor in del7q AML; ABCB8 loss impairs KDM6A demethylase via iron depletion, raises H3K27me3, cooperates with KMT2C to suppress leukemogenesis. Purely preclinical.

🟥 TOPIC 2: CBC-Based Diagnostics and Machine Learning

1 found · 1 reviewed · 1 HIGH

PMID 42421054 — BMC Med | Score 9/10

Multimodal DNN on CBC digit parameters + scattergrams for hematolymphoid malignancy classification (multicenter)
Liao H, Chen S, Meng Q, … Liu Y, Zheng Q · BMC Med · 2026-07-08
DOI: 10.1186/s12916-026-05036-y | Open access

Key finding: mDNN-cHM integrating CBC numeric parameters and WBC scattergram image achieves AUC 0.98–1.00 (internal) and 0.95–1.00 (external) for classifying 6 hematolymphoid malignancy subtypes vs acute infection in 4,996 patients across 6 centers; results in <0.5 h from sample receipt; outperforms current CBC review rules.

Exactly on-target for the CBC-ML watchlist. Multicenter AUC ≥0.95 with external validation meets the highest bar for diagnostic AI readiness. The scattergram-plus-digits multimodal approach is conceptually novel. Most impactful T2 article in recent months.

🟥 TOPIC 3: Early Cancer Detection (Liquid Biopsy, ctDNA, cfRNA)

25 found · 15 reviewed · 1 HIGH · 1 MEDIUM

PMID 42425994 — Nat Commun | Score 8/10

GeneLLM: decoding cancer cfRNA signatures with Transformer language models
Deng S, Sha L, Jin Y, … Chen S, Wang P · Nat Commun · 2026-07-09
DOI: 10.1038/s41467-026-74411-3 | Open access

Key finding: Transformer model operating on raw cfRNA nucleotide sequences bypasses gene annotation, captures "transcriptomic dark matter," achieves AUC 0.9250–0.9962 across multiple cancer types in multi-centre cohort at one-sixth standard sequencing depth.

Conceptually novel cfRNA approach: LM processes sequence directly rather than gene-level counts, retaining signals from unannotated repetitive regions. Multi-cancer multi-centre AUC ≥0.92 at greatly reduced sequencing cost. Nature Communications. Proof-of-concept stage—prospective clinical validation required.

PMID 42425884 — Urol Oncol | Score 6/10 [MEDIUM]

Urine tumor DNA (utLIFE) dynamics predict recurrence in upper tract urothelial carcinoma (prospective)
Zuo W, Tang Q, Guo X, … Zhou L, Li X · Urol Oncol · 2026-07-09
DOI: 10.1016/j.urolonc.2026.06.011

Key finding: utLIFE 83.3% sensitivity for bladder recurrence prediction vs 16.7% for cystoscopy; 5.67-month lead time before radiographic detection; dynamic utLIFE trajectory independently predicts recurrence-free survival. n=47.

🟥 TOPIC 4: AI/ML in Clinical Diagnostics and Imaging

86 found · 15 reviewed · 5 HIGH

(Note: PMIDs 42426209 [PNH-AI, T1/T4] and 42425502 [CVD risk, T7/T4] also scored HIGH under their primary topics above.)

PMID 42424436 — Science | Score 8/10 [see Sentinel section above]

PMID 42425502 — Eur Heart J | Score 8/10 [see Topic 7 below]

PMID 42426209 — NPJ Digit Med | Score 9/10 [see Topic 1 above]

PMID 42425805 — Acad Radiol | Score 8/10

3D V-Net + 4B-parameter MedGemma LLM for csPCa detection on mpMRI: multi-institutional validation
Wang K, Gao G, Wang H, Wu J, Wang X, Wu P, Wang X · Acad Radiol · 2026-07-09
DOI: 10.1016/j.acra.2026.06.029

Key finding: Combined 3D segmentation + LLM achieves AUROC 0.900 in external validation of 1,154 patients for csPCa on mpMRI; outperforms all single models (ΔAUROC 0.060–0.145); superior clinical benefit on DCA across thresholds 0.3–0.9.

Multi-institutional 5,050-patient dataset with rigorous external validation and DCA confirms clinical utility. LLM integration with 3D segmentation is technically novel. Addresses the high-burden problem of MRI-based PCa triage.

PMID 42426365 — Nat Comput Sci | Score 7/10

DISSECT: integrating cytological images and spatial transcriptomics for cell segmentation
He Y, Zhao Y, Zhang R, … Pan D, Zeng Z · Nat Comput Sci · 2026-07-09
DOI: 10.1038/s43588-026-01020-x

Key finding: Deep generative model integrating image + transcriptomic gradients outperforms existing spatial transcriptomics segmentation tools; applied to gastric adenocarcinoma pre/post anti-PD-1 for spatial immune profiling.

Nature Computational Science methodology paper enabling downstream spatial biology for immuno-oncology research. Research tool rather than direct clinical application.

🟥 TOPIC 5: Precision Oncology and Genomic Medicine

18 found · 15 reviewed · 1 HIGH

PMID 42426002 — Nat Commun | Score 9/10 [see main ranking above]

NEVA: vision-language foundation model for neuroblastoma (11 tasks, 1,238 patients)
Also indexed under: T4 (AI/ML) · T9 (Rare disease — paediatric cancer)

🟥 TOPIC 6: Novel Therapeutics (Immunotherapy, CAR-T, Targeted Therapy)

123 found · 15 reviewed · 1 HIGH

PMID 42425951 — Signal Transduct Target Ther | Score 8/10

Multifunctional-engineered NK cells overcome immunosuppression via PD-L1/HLA-E dual targeting + IL15
Fiore PF, Forcelloni S, Moretta L, … Tumino N, Caruana I, Vacca P · STTT · 2026-07-10
DOI: 10.1038/s41392-026-02827-w | Open access

Key finding: Tri-cistronic retroviral vector encoding exPD1-NKG2D-4-1BB + NKG2A-scFv + IL15 simultaneously converts PD-L1 inhibition to activation, masks HLA-E-mediated suppression, and prevents NK exhaustion; pan-cancer activity in preclinical models; allogenic "ready-to-use" platform.

Signal Transduct Target Ther (Nature group); most ambitious NK cell engineering construct reported this window—simultaneously addressing three independent immunosuppression mechanisms in a single vector. Allogenic platform addresses CAR-T manufacturing bottleneck. Preclinical only; scored design_quality conservatively.

🟥 TOPIC 7: Cardiovascular-Metabolic (GLP-1, SGLT2, Cardiometabolic)

62 found · 15 reviewed · 2 HIGH · 2 MEDIUM

PMID 42426287 — Nat Metab | Score 8/10

GLP-1RA discontinuation associated with increased depression and anxiety risk (EHR cohort)
Zhang T, He P, Ji Y, … Wang W, Ning G · Nat Metab · 2026-07-09
DOI: 10.1038/s42255-026-01567-z

Key finding: GLP-1RA cessation increases incident depression/anxiety risk compared with DPP4i or SGLT2i cessation; not seen during active treatment; effect partially mediated by triglyceride rebound; Shanghai Hospital Link Database (large-scale EHR).

Novel pharmacovigilance signal with major public health implications given millions of GLP-1RA prescriptions annually. Nature Metabolism. Observational design limits causality but active-comparator design strengthens validity. Clinical vigilance warranted for patients discontinuing GLP-1RAs.

PMID 42425502 — Eur Heart J | Score 8/10

China-AIHeart: transformer-based 10-year CVD risk models for Chinese adults (156K derivation)
Cao Q, Xu X, Lin H, … Wang W, Bi Y, Lu J · Eur Heart J · 2026-07-09
DOI: 10.1093/eurheartj/ehag517

Key finding: Sex-specific transformer models (C-stat 0.767–0.780) derived from 156,790 Chinese adults and validated in two external cohorts; ΔNRI 0.478–0.560 over Cox; outperforms China-PAR, PREVENT-ASCVD, and SCORE2 Asia-Pacific.

European Heart Journal; largest Chinese CVD risk prediction development + dual external validation study; transformer advantage over Cox confirmed with quantified NRI improvement.

🟥 TOPIC 8: Aging, Longevity, and Population Health

12 found · 12 reviewed · 0 HIGH · 1 MEDIUM

PMID 42421064 — BMC Med | Score 5/10 [MEDIUM]

Comparing geriatric assessment tools for predicting negative health outcomes in older adults
Abbadi A, Innocenti F, Beridze G, … Vetrano DL, Calderón-Larrañaga A · BMC Med · 2026-07-09
DOI: 10.1186/s12916-026-05008-2 | Open access

Key finding: Head-to-head comparison of geriatric assessment tools for predicting hospitalisation, functional decline, and mortality in older adults; provides evidence base for tool selection in geriatric clinical practice.

Best available T8 article in this window. Low signal day for aging/longevity—no high-priority clinical or translational finding. Tool comparison without intervention evidence caps score.

🟥 TOPIC 9: Rare Diseases with High Unmet Need

21 found · 15 reviewed · 3 HIGH · 2 MEDIUM

PMID 42426002 — Nat Commun | Score 9/10 [HIGH]

NEVA neuroblastoma VLM [See Topic 5 above]

PMID 42426151 — Eur J Hum Genet | Score 7/10 [HIGH]

RareBoost: integrative genomics achieves 50.8% yield in previously unsolved rare diseases
Yigit A, Pekerbas M, Salman B, … Batur T, Ozbek U · Eur J Hum Genet · 2026-07-09
DOI: 10.1038/s41431-026-02177-9

Key finding: Stepwise exome + genome + RNA-seq strategy in 120 previously unresolved rare disease families achieved 25.0% definitive + 25.8% actionable uncertain-significance diagnostic yield; non-coding and structural variants resolved; scalable framework demonstrated.

PMID 42425729 — Eur Respir J | Score 7/10 [HIGH]

Lung transplantation for pulmonary alveolar proteinosis: international multicenter analysis
Schwarz S, Prosch H, Yekeler E, … Jaksch P, Hoetzenecker K · Eur Respir J · 2026-07-09
DOI: 10.1183/13993003.02351-2025

Key finding: First international multicenter analysis of LTx outcomes for pulmonary alveolar proteinosis (PAP); 37 centres; provides evidence base for transplant listing in refractory PAP where current data is limited to case series.

PMID 42426296 — Br J Cancer | Score 5/10 [MEDIUM]

Paediatric therapeutic development workshop: medulloblastoma priorities
Montiel Equihua C, Baxter JS, Molenaar JJ, … Doz F, Clifford SC · Br J Cancer · 2026-07-09
DOI: 10.1038/s41416-026-03533-8 | Open access

Key finding: Workshop identifies SRC degraders, c-MYC/MYCN inhibitors, radiolabelled theranostic B7-H3 antibodies, and B7-H3 CAR-T/ADC as priorities for medulloblastoma; CNS-penetrant PARP1/CHK1-2 + ATR combos for high-risk patients.

PMID 42425402 — Life Sci | Score 6/10 [MEDIUM]

P4hb(Y393C) mouse model of Cole-Carpenter syndrome + therapeutic proof-of-concept
Maurizi A, Pucci E, Patrizii P, Silvestri L, Rucci N, Capulli M · Life Sci · 2026-07-09
DOI: 10.1016/j.lfs.2026.124593

Key finding: First CCS mouse model; FDA-approved drug screen identifies 4 collagen-enhancing compounds; allele-specific siRNA silences mutant P4HB allele selectively; translational potential for this untreatable skeletal rare disease.

📊 Coverage Summary

Top journals today: Lancet (×2) · Nature Communications (×3) · Science · Nature Metabolism · Nature Computational Science · Signal Transduction and Targeted Therapy · European Heart Journal · NPJ Digital Medicine

Pipeline Triage v1.3 · Attempt 1/3 · Generated 2026-07-10T09:07Z